171 related articles for article (PubMed ID: 22372798)
1. Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
Argüelles-Arias F; Castro-Laria L; Barreiro-de Acosta M; García-Sánchez MV; Guerrero-Jiménez P; Gómez-García MR; Cordero-Ruiz P; Iglesias-Flores E; Gómez-Camacho F; Domínguez-Muñoz EJ; Herrerías-Gutiérrez JM
Rev Esp Enferm Dig; 2012 Feb; 104(2):59-64. PubMed ID: 22372798
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.
Bortlik M; Machkova N; Duricova D; Malickova K; Hrdlicka L; Lukas M; Kohout P; Shonova O; Lukas M
Scand J Gastroenterol; 2013 Aug; 48(8):951-8. PubMed ID: 23834232
[TBL] [Abstract][Full Text] [Related]
3. Exposure to Infliximab During Pregnancy: Post-Marketing Experience.
Geldhof A; Slater J; Clark M; Chandran U; Coppola D
Drug Saf; 2020 Feb; 43(2):147-161. PubMed ID: 31677004
[TBL] [Abstract][Full Text] [Related]
4. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
6. Intrapartum corticosteroid use significantly increases the risk of gestational diabetes in women with inflammatory bowel disease.
Leung YP; Kaplan GG; Coward S; Tanyingoh D; Kaplan BJ; Johnston DW; Barkema HW; Ghosh S; Panaccione R; Seow CH; ;
J Crohns Colitis; 2015 Mar; 9(3):223-30. PubMed ID: 25576754
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.
El Mourabet M; El-Hachem S; Harrison JR; Binion DG
Curr Drug Targets; 2010 Feb; 11(2):234-41. PubMed ID: 19916950
[TBL] [Abstract][Full Text] [Related]
8. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
[TBL] [Abstract][Full Text] [Related]
9. Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease.
Truta B; Leeds IL; Canner JK; Efron JE; Fang SH; Althumari A; Safar B
Inflamm Bowel Dis; 2020 Jun; 26(7):1110-1117. PubMed ID: 31670762
[TBL] [Abstract][Full Text] [Related]
10. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.
Mahadevan U; Kane S; Sandborn WJ; Cohen RD; Hanson K; Terdiman JP; Binion DG
Aliment Pharmacol Ther; 2005 Mar; 21(6):733-8. PubMed ID: 15771759
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
12. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study.
Molnár T; Farkas K; Nagy F; Lakatos PL; Miheller P; Nyári T; Horváth G; Szepes Z; Marik A; Wittmann T
Scand J Gastroenterol; 2010 Nov; 45(11):1302-6. PubMed ID: 20602569
[TBL] [Abstract][Full Text] [Related]
14. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
15. Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease.
van den Berg SA; de Boer M; van der Meulen-de Jong AE; Jansen JM; Hoentjen F; Russel MG; Mahmmod N; van Bodegraven AA; van der Woude CJ; Mulder CJ; de Boer NK
J Crohns Colitis; 2016 Feb; 10(2):159-65. PubMed ID: 26503525
[TBL] [Abstract][Full Text] [Related]
16. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.
Coelho J; Beaugerie L; Colombel JF; Hébuterne X; Lerebours E; Lémann M; Baumer P; Cosnes J; Bourreille A; Gendre JP; Seksik P; Blain A; Metman EH; Nisard A; Cadiot G; Veyrac M; Coffin B; Dray X; Carrat F; Marteau P;
Gut; 2011 Feb; 60(2):198-203. PubMed ID: 21115547
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.
Mozaffari S; Abdolghaffari AH; Nikfar S; Abdollahi M
Hum Exp Toxicol; 2015 May; 34(5):445-59. PubMed ID: 25378092
[TBL] [Abstract][Full Text] [Related]
19. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
